Patents Assigned to Philera New Zealand Limited
-
Patent number: 11795150Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.Type: GrantFiled: August 8, 2019Date of Patent: October 24, 2023Assignee: Philera New Zealand LimitedInventors: Marco Jonas, Irene Vaulont, Antonio Soi, Gunther Schmidt
-
Patent number: 11419831Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: GrantFiled: December 18, 2019Date of Patent: August 23, 2022Assignee: PhilEra New Zealand LimitedInventor: Garth James Smith Cooper
-
Publication number: 20200276135Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: ApplicationFiled: December 18, 2019Publication date: September 3, 2020Applicant: PhilEra New Zealand LimitedInventor: Garth James Smith Cooper
-
Patent number: 10543178Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: GrantFiled: April 30, 2018Date of Patent: January 28, 2020Assignee: Philera New Zealand LimitedInventor: Garth James Smith Cooper
-
Publication number: 20190000778Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: ApplicationFiled: April 30, 2018Publication date: January 3, 2019Applicant: PhilERA New Zealand LimitedInventor: Garth James Smith Cooper
-
Patent number: 9993443Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogs, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: GrantFiled: July 22, 2016Date of Patent: June 12, 2018Assignee: PhilEra New Zealand LimitedInventor: Garth James Smith Cooper
-
Publication number: 20170226064Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.Type: ApplicationFiled: May 3, 2017Publication date: August 10, 2017Applicant: PhilEra New Zealand LimitedInventors: Marco Jonas, Irene Vaulont, Antonio Soi, Gunther Schmidt
-
Patent number: 9556123Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.Type: GrantFiled: June 10, 2015Date of Patent: January 31, 2017Assignee: Philera New Zealand LimitedInventors: Marco Jonas, Irene Vaulont, Antonio Soi, Gunther Schmidt
-
Publication number: 20160324804Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: ApplicationFiled: July 22, 2016Publication date: November 10, 2016Applicant: PhilEra New Zealand LimitedInventors: Garth James Smith Cooper, John Richard Baker, Nigel Robert Arnold Beeley
-
Patent number: 9339479Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogs, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: GrantFiled: December 17, 2014Date of Patent: May 17, 2016Assignee: PHILERA NEW ZEALAND LIMITEDInventor: Garth James Smith Cooper
-
Publication number: 20150196500Abstract: Pharmaceutical compositions and methods for the treatment of subjects, including humans, who have or are at risk for various disease, disorders and conditions, including, mitochondria-associated diseases, disorders, and conditions, including respiratory chain disorders, and diseases, disorders and conditions associated with or characterized at least in part by mitochondria swelling, mitochondria dysfunction, mitochondria leaking, oxidative stress, increased mitochondria number, increased mitochondria and mitochondria-related protein mass, and increased mitochondria and related-related proteins expression.Type: ApplicationFiled: December 15, 2014Publication date: July 16, 2015Applicant: PHILERA NEW ZEALAND LIMITEDInventors: Garth James, Smith COOPER, Anthony Ronald, John PHILLIPS, Nancy Xiuyin CHEN, Deming GONG, Maria JULLIG, Anthony John, Rodney HICKEY, Sarah GLYN-JONES
-
Publication number: 20150164826Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.Type: ApplicationFiled: December 17, 2014Publication date: June 18, 2015Applicant: PhilEra New Zealand LimitedInventors: Garth James Smith Cooper, John Richard Baker, Nigel Robert Arnold Beeley
-
Patent number: 8987244Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the hType: GrantFiled: September 18, 2013Date of Patent: March 24, 2015Assignee: PhilERA New Zealand LimitedInventors: Garth J. S. Cooper, John R. Baker
-
Patent number: 8912362Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.Type: GrantFiled: January 25, 2013Date of Patent: December 16, 2014Assignee: Philera New Zealand LimitedInventors: Marco Jonas, Irene Vaulont, Antonio Soi, Gunther Schmidt
-
Publication number: 20140113969Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) drug induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the hType: ApplicationFiled: September 18, 2013Publication date: April 24, 2014Applicant: PHILERA NEW ZEALAND LIMITEDInventors: Garth J.S. Cooper, John R. Baker
-
Publication number: 20130345311Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.Type: ApplicationFiled: January 25, 2013Publication date: December 26, 2013Applicant: PHILERA NEW ZEALAND LIMITEDInventor: PHILERA NEW ZEALAND LIMITED
-
Patent number: 8563538Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidneyType: GrantFiled: February 28, 2011Date of Patent: October 22, 2013Assignee: Philera New Zealand LimitedInventors: Garth J. S. Cooper, John R. Baker
-
Patent number: 8394992Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.Type: GrantFiled: October 7, 2011Date of Patent: March 12, 2013Assignee: PhilEra New Zealand LimitedInventors: Marco Jonas, Irene Vaulont, Antonio Soi, Gunther Schmidt
-
Publication number: 20120029203Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.Type: ApplicationFiled: October 7, 2011Publication date: February 2, 2012Applicant: PHILERA NEW ZEALAND LIMITEDInventors: Marco Jonas, Irene Vaulont, Antonio Soi, Gunther Schmidt
-
Patent number: 8067641Abstract: Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.Type: GrantFiled: July 21, 2009Date of Patent: November 29, 2011Assignee: Philera New Zealand LimitedInventors: Marco Jonas, Irene Vaulont, Antonio Soi, Gunther Schmidt